 Connection
Christopher Porter to Neoplasms
This is a "connection" page, showing publications Christopher Porter has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.665 |
|
|
|
-
Perrino MR, MacFarland SP, Maese L, Vagher J, Kamihara J, Rednam S, Lupo PJ, Brodeur GM, Schiffman J, Diller L, Desrosiers-Battu L, Plon SE, Nichols KE, Volchenboum SL, Malkin D, Villani A, Porter CC. Childhood cancer predisposition study: a prospective registry and biorepository protocol. BMJ Open. 2026 08 05; 16(8):e120576.
Score: 0.324
-
Mitchell SG, Pencheva B, Westfall E, Porter CC. Cancer Predisposition in Neonates and Infants: Recognition, Tumor Types, and Surveillance. Clin Perinatol. 2021 03; 48(1):1-14.
Score: 0.220
-
Juarez OA, Pencheva BB, Bellcross C, Schneider KW, Turner J, Porter CC. Cancer genetic counseling for childhood cancer predisposition is associated with improved levels of knowledge and high satisfaction in parents. J Genet Couns. 2021 06; 30(3):710-719.
Score: 0.218
-
Gore L, DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success? Lancet Oncol. 2013 Feb; 14(2):e70-8.
Score: 0.127
-
Lin HK, Blake DA, Freeman R, Chen Y, Kim J, Johnson AM, Wells K, Mudigonda A, Liu W, Yadav P, Zeng F, Muhuri A, Min K, Sarkar S, Wang Y, Goyal S, Roberts RC, Christensen E, Ward AB, Heller B, Chun P, Dougan J, Porter CC, Barwick BG, Paulos CM, Yang L, Patgiri A, Thomas SN, Waller EK, Rafiq S. Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models. Sci Transl Med. 2026 Jul 22; 18(859):eadt9565.
Score: 0.081
-
Kamihara J, Fisher L, Schienda J, Vanderwall R, Snir M, Snir G, Simmons E, Khalaj A, Goler E, Hamilton KV, Porter CC, Pencheva B, Schiffman JD, Maese LD, Kohlmann W, Henderson TO, Garber JE, Diller LR, Desai AV, Savage S, Klosky JL, Rana HQ, Mack JW. Development and pilot testing of AYA-RISE, a risk information and screening education intervention for adolescents and young adults with cancer risk syndromes. Fam Cancer. 2026 01 23; 25(1):11.
Score: 0.078
-
Fuentes Bolanos NA, Lupo PJ, Tucker KM, Hawkins DS, Porter CC, Villani A, Spector LG. Frequency and face validity of reported family history of cancer in first-degree relatives and genetic syndromes among children with cancer in Project:EveryChild: A report from the Children's Oncology Group. Cancer. 2026 Jan 01; 132(1):e70231.
Score: 0.078
-
Brodeur GM, Diller LR, Nichols KE, Plon SE, Porter CC, Malkin D. Pediatric Cancer Predisposition and Surveillance Update: Summary Perspective and Future Directions. Clin Cancer Res. 2025 Jul 01; 31(13):2581-2588.
Score: 0.075
-
Nakano Y, Kuiper RP, Nichols KE, Porter CC, Lesmana H, Meade J, Kratz CP, Godley LA, Maese LD, Achatz MI, Khincha PP, Savage SA, Doria AS, Greer MC, Chang VY, Wang LL, Plon SE, Walsh MF. Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders. Clin Cancer Res. 2024 Nov 15; 30(22):5009-5020.
Score: 0.072
-
Alvarez SJA, Pencheva B, Westfall E, Mwalija C, Parsell M, Greenleaf M, Porter CC, Lam WA, Mannino RG, Mitchell SG. A novel mobile health application to support cancer surveillance needs of patients and families with cancer predisposition syndromes. Pediatr Blood Cancer. 2023 10; 70(10):e30537.
Score: 0.065
-
Birnbaum LA, Sullivan EC, Do P, Uricoli B, Raikar SS, Porter CC, Henry CJ, Dreaden EC. Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines. Biomacromolecules. 2023 03 13; 24(3):1164-1172.
Score: 0.064
-
MacFarland SP, Maese L, Rednam SP, Kamihara J, Perrino MR, Nichols KE, Brodeur GM, Schiffman JD, Plon SE, Diller LR, Malkin D, Porter CC, Villani A. Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition. Cancer Prev Res (Phila). 2022 10 04; 15(10):645-652.
Score: 0.062
-
Summers RJ, Castellino SM, Porter CC, MacDonald TJ, Basu GD, Szelinger S, Bhasin MK, Cash T, Carter AB, Castellino RC, Fangusaro JR, Mitchell SG, Pauly MG, Pencheva B, Wechsler DS, Graham DK, Goldsmith KC. Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care. JCO Precis Oncol. 2022 04; 6:e2100451.
Score: 0.060
-
Uricoli B, Birnbaum LA, Do P, Kelvin JM, Jain J, Costanza E, Chyong A, Porter CC, Rafiq S, Dreaden EC. Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Adv Healthc Mater. 2021 08; 10(15):e2002214.
Score: 0.056
-
Walsh MF, Chang VY, Kohlmann WK, Scott HS, Cunniff C, Bourdeaut F, Molenaar JJ, Porter CC, Sandlund JT, Plon SE, Wang LL, Savage SA. Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. Clin Cancer Res. 2017 Jun 01; 23(11):e23-e31.
Score: 0.043
-
Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017 04; 15(4):382-394.
Score: 0.042
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|